Serina Therapeutics CEO Steve Ledger base salary rises to $500,000 under amended employment deal
SER•Severance and change-in-control terms
- Without-cause termination or good-reason resignation outside a change in control triggers 12 months base salary, pro-rated target bonus, 12 months COBRA.
- Qualifying change-in-control termination triggers 1.5x base salary, 1.5x target bonus, pro-rated target bonus, 18 months COBRA.
- Change-in-control terms include full accelerated vesting of unvested time-based equity awards; parachute benefits subject to best-net reduction, no excise-tax gross-up.
Amended employment agreement sets higher salary and bonus target
Serina Therapeutics entered an amended and restated employment agreement with CEO Steve Ledger on July 19, 2026.
- Sets annual base salary at USD 500,000; target annual bonus set at 50% of base salary.
